We evaluated the efficacy and safety of triple antiemetic therapy with aprepitant , a @-hydroxytryptamine-@ ( @-HT ( @ ) ) receptor antagonist , and dexamethasone in patients with advanced non-small-cell lung cancer ( NSCLC ) who received carboplatin-based first-line chemotherapy .